RenovoRx (RNXT)

• Market cap: $30M
• 1 day: 8.70%
• 5 days: -5.30%
• 1 month: 5.04%
• 3 months: 2.46%
• 6 months: -3.85%
• Year to date: -36.87%
• 1 year: 76.06%
• 5 years: -82.78%
• 10 years: -82.78%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Employees: 8

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

98% more capital invested

Capital invested by funds: $1.01M [Q2] → $2M (+$992K) [Q3]

4.14% more ownership

Funds ownership: 3.74% [Q2] → 7.88% (+4.14%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

24% less funds holding

Funds holding: 17 [Q2] → 13 (-4) [Q3]

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $9 620% upside
• Avg. target: $9 620% upside
• High target: $9 620% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Ascendiant Capital Edward Woo 38% 1-year accuracy 28 / 73 met price target

620% upside $9

Buy Maintained

10 Dec 2024